A model of HIV-1 pathogenesis that includes an intracellular delay
Mathematical modeling combined with experimental measurements have yielded important insights into HIV-1 pathogenesis. For example, data from experiments in which HIV-infected patients are given potent antiretroviral drugs that perturb the infection process have been used to estimate kinetic paramet...
Gespeichert in:
Veröffentlicht in: | Mathematical biosciences 2000-02, Vol.163 (2), p.201-215 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 215 |
---|---|
container_issue | 2 |
container_start_page | 201 |
container_title | Mathematical biosciences |
container_volume | 163 |
creator | Nelson, Patrick W. Murray, James D. Perelson, Alan S. |
description | Mathematical modeling combined with experimental measurements have yielded important insights into HIV-1 pathogenesis. For example, data from experiments in which HIV-infected patients are given potent antiretroviral drugs that perturb the infection process have been used to estimate kinetic parameters underlying HIV infection. Many of the models used to analyze data have assumed drug treatments to be completely efficacious and that upon infection a cell instantly begins producing virus. We consider a model that allows for less then perfect drug effects and which includes a delay in the initiation of virus production. We present detailed analysis of this delay differential equation model and compare the results to a model without delay. Our analysis shows that when drug efficacy is less than 100%, as may be the case in vivo, the predicted rate of decline in plasma virus concentration depends on three factors: the death rate of virus producing cells, the efficacy of therapy, and the length of the delay. Thus, previous estimates of infected cell loss rates can be improved upon by considering more realistic models of viral infection. |
doi_str_mv | 10.1016/S0025-5564(99)00055-3 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70944188</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0025556499000553</els_id><sourcerecordid>17508028</sourcerecordid><originalsourceid>FETCH-LOGICAL-c473t-8413b3514f34cdfb7771b4ec24c2a5df93eb6c6482fff40d0ab0d8fb3bff16ff3</originalsourceid><addsrcrecordid>eNqFkE1P3DAQhq0KVBbKTyjKAVX0EDoT23F8QhTRgoTEgY-r5dhjcJVNtnZSiX9Pll21vXGaOTzvzKuHsc8IpwhYf7sDqGQpZS1OtP4KAFKW_ANbYKN0yZGLHbb4i-yx_Zx_AaBCrD-yPQQFyEEs2PfzYjl46oohFFfXjyUWKzs-D0_UU465GJ_tWMTedZOnXNh-3sdkHXXd1NlUzEH78ontBttlOtzOA_bw4_L-4qq8uf15fXF-Uzqh-Fg2AnnLJYrAhfOhVUphK8hVwlVW-qA5tbWrRVOFEAR4sC34JrS8DQHrEPgB-7K5u0rD74nyaJYxr6vYnoYpGwVaCGyad0FUEhqo1qDcgC4NOScKZpXi0qYXg2DWls2bZbNWaLQ2b5YNn3NH2wdTuyT_X2qjdQaOt4DNznYh2d7F_I-rNAqhZ-xsg9Gs7U-kZLKL1DvyMZEbjR_iO01eAQwVmBQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17508028</pqid></control><display><type>article</type><title>A model of HIV-1 pathogenesis that includes an intracellular delay</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Nelson, Patrick W. ; Murray, James D. ; Perelson, Alan S.</creator><creatorcontrib>Nelson, Patrick W. ; Murray, James D. ; Perelson, Alan S.</creatorcontrib><description>Mathematical modeling combined with experimental measurements have yielded important insights into HIV-1 pathogenesis. For example, data from experiments in which HIV-infected patients are given potent antiretroviral drugs that perturb the infection process have been used to estimate kinetic parameters underlying HIV infection. Many of the models used to analyze data have assumed drug treatments to be completely efficacious and that upon infection a cell instantly begins producing virus. We consider a model that allows for less then perfect drug effects and which includes a delay in the initiation of virus production. We present detailed analysis of this delay differential equation model and compare the results to a model without delay. Our analysis shows that when drug efficacy is less than 100%, as may be the case in vivo, the predicted rate of decline in plasma virus concentration depends on three factors: the death rate of virus producing cells, the efficacy of therapy, and the length of the delay. Thus, previous estimates of infected cell loss rates can be improved upon by considering more realistic models of viral infection.</description><identifier>ISSN: 0025-5564</identifier><identifier>EISSN: 1879-3134</identifier><identifier>DOI: 10.1016/S0025-5564(99)00055-3</identifier><identifier>PMID: 10701304</identifier><identifier>CODEN: MABIAR</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>AIDS/HIV ; Anti-HIV Agents - therapeutic use ; Biological and medical sciences ; Delay ; HIV ; HIV Infections - drug therapy ; HIV Infections - etiology ; HIV Protease Inhibitors - therapeutic use ; HIV-1 - drug effects ; Human immunodeficiency virus ; Human viral diseases ; Humans ; Infectious diseases ; Lamivudine - therapeutic use ; Medical sciences ; Models, Biological ; Numerical Analysis, Computer-Assisted ; Reverse Transcriptase Inhibitors - therapeutic use ; T-cells ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids ; Viral life cycle ; Zidovudine - therapeutic use</subject><ispartof>Mathematical biosciences, 2000-02, Vol.163 (2), p.201-215</ispartof><rights>2000 Elsevier Science Inc.</rights><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c473t-8413b3514f34cdfb7771b4ec24c2a5df93eb6c6482fff40d0ab0d8fb3bff16ff3</citedby><cites>FETCH-LOGICAL-c473t-8413b3514f34cdfb7771b4ec24c2a5df93eb6c6482fff40d0ab0d8fb3bff16ff3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0025556499000553$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1291449$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10701304$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nelson, Patrick W.</creatorcontrib><creatorcontrib>Murray, James D.</creatorcontrib><creatorcontrib>Perelson, Alan S.</creatorcontrib><title>A model of HIV-1 pathogenesis that includes an intracellular delay</title><title>Mathematical biosciences</title><addtitle>Math Biosci</addtitle><description>Mathematical modeling combined with experimental measurements have yielded important insights into HIV-1 pathogenesis. For example, data from experiments in which HIV-infected patients are given potent antiretroviral drugs that perturb the infection process have been used to estimate kinetic parameters underlying HIV infection. Many of the models used to analyze data have assumed drug treatments to be completely efficacious and that upon infection a cell instantly begins producing virus. We consider a model that allows for less then perfect drug effects and which includes a delay in the initiation of virus production. We present detailed analysis of this delay differential equation model and compare the results to a model without delay. Our analysis shows that when drug efficacy is less than 100%, as may be the case in vivo, the predicted rate of decline in plasma virus concentration depends on three factors: the death rate of virus producing cells, the efficacy of therapy, and the length of the delay. Thus, previous estimates of infected cell loss rates can be improved upon by considering more realistic models of viral infection.</description><subject>AIDS/HIV</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Delay</subject><subject>HIV</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - etiology</subject><subject>HIV Protease Inhibitors - therapeutic use</subject><subject>HIV-1 - drug effects</subject><subject>Human immunodeficiency virus</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Lamivudine - therapeutic use</subject><subject>Medical sciences</subject><subject>Models, Biological</subject><subject>Numerical Analysis, Computer-Assisted</subject><subject>Reverse Transcriptase Inhibitors - therapeutic use</subject><subject>T-cells</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><subject>Viral life cycle</subject><subject>Zidovudine - therapeutic use</subject><issn>0025-5564</issn><issn>1879-3134</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1P3DAQhq0KVBbKTyjKAVX0EDoT23F8QhTRgoTEgY-r5dhjcJVNtnZSiX9Pll21vXGaOTzvzKuHsc8IpwhYf7sDqGQpZS1OtP4KAFKW_ANbYKN0yZGLHbb4i-yx_Zx_AaBCrD-yPQQFyEEs2PfzYjl46oohFFfXjyUWKzs-D0_UU465GJ_tWMTedZOnXNh-3sdkHXXd1NlUzEH78ontBttlOtzOA_bw4_L-4qq8uf15fXF-Uzqh-Fg2AnnLJYrAhfOhVUphK8hVwlVW-qA5tbWrRVOFEAR4sC34JrS8DQHrEPgB-7K5u0rD74nyaJYxr6vYnoYpGwVaCGyad0FUEhqo1qDcgC4NOScKZpXi0qYXg2DWls2bZbNWaLQ2b5YNn3NH2wdTuyT_X2qjdQaOt4DNznYh2d7F_I-rNAqhZ-xsg9Gs7U-kZLKL1DvyMZEbjR_iO01eAQwVmBQ</recordid><startdate>20000201</startdate><enddate>20000201</enddate><creator>Nelson, Patrick W.</creator><creator>Murray, James D.</creator><creator>Perelson, Alan S.</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20000201</creationdate><title>A model of HIV-1 pathogenesis that includes an intracellular delay</title><author>Nelson, Patrick W. ; Murray, James D. ; Perelson, Alan S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c473t-8413b3514f34cdfb7771b4ec24c2a5df93eb6c6482fff40d0ab0d8fb3bff16ff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>AIDS/HIV</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Delay</topic><topic>HIV</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - etiology</topic><topic>HIV Protease Inhibitors - therapeutic use</topic><topic>HIV-1 - drug effects</topic><topic>Human immunodeficiency virus</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Lamivudine - therapeutic use</topic><topic>Medical sciences</topic><topic>Models, Biological</topic><topic>Numerical Analysis, Computer-Assisted</topic><topic>Reverse Transcriptase Inhibitors - therapeutic use</topic><topic>T-cells</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><topic>Viral life cycle</topic><topic>Zidovudine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nelson, Patrick W.</creatorcontrib><creatorcontrib>Murray, James D.</creatorcontrib><creatorcontrib>Perelson, Alan S.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Mathematical biosciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nelson, Patrick W.</au><au>Murray, James D.</au><au>Perelson, Alan S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A model of HIV-1 pathogenesis that includes an intracellular delay</atitle><jtitle>Mathematical biosciences</jtitle><addtitle>Math Biosci</addtitle><date>2000-02-01</date><risdate>2000</risdate><volume>163</volume><issue>2</issue><spage>201</spage><epage>215</epage><pages>201-215</pages><issn>0025-5564</issn><eissn>1879-3134</eissn><coden>MABIAR</coden><abstract>Mathematical modeling combined with experimental measurements have yielded important insights into HIV-1 pathogenesis. For example, data from experiments in which HIV-infected patients are given potent antiretroviral drugs that perturb the infection process have been used to estimate kinetic parameters underlying HIV infection. Many of the models used to analyze data have assumed drug treatments to be completely efficacious and that upon infection a cell instantly begins producing virus. We consider a model that allows for less then perfect drug effects and which includes a delay in the initiation of virus production. We present detailed analysis of this delay differential equation model and compare the results to a model without delay. Our analysis shows that when drug efficacy is less than 100%, as may be the case in vivo, the predicted rate of decline in plasma virus concentration depends on three factors: the death rate of virus producing cells, the efficacy of therapy, and the length of the delay. Thus, previous estimates of infected cell loss rates can be improved upon by considering more realistic models of viral infection.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>10701304</pmid><doi>10.1016/S0025-5564(99)00055-3</doi><tpages>15</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0025-5564 |
ispartof | Mathematical biosciences, 2000-02, Vol.163 (2), p.201-215 |
issn | 0025-5564 1879-3134 |
language | eng |
recordid | cdi_proquest_miscellaneous_70944188 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | AIDS/HIV Anti-HIV Agents - therapeutic use Biological and medical sciences Delay HIV HIV Infections - drug therapy HIV Infections - etiology HIV Protease Inhibitors - therapeutic use HIV-1 - drug effects Human immunodeficiency virus Human viral diseases Humans Infectious diseases Lamivudine - therapeutic use Medical sciences Models, Biological Numerical Analysis, Computer-Assisted Reverse Transcriptase Inhibitors - therapeutic use T-cells Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Viral life cycle Zidovudine - therapeutic use |
title | A model of HIV-1 pathogenesis that includes an intracellular delay |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T20%3A07%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20model%20of%20HIV-1%20pathogenesis%20that%20includes%20an%20intracellular%20delay&rft.jtitle=Mathematical%20biosciences&rft.au=Nelson,%20Patrick%20W.&rft.date=2000-02-01&rft.volume=163&rft.issue=2&rft.spage=201&rft.epage=215&rft.pages=201-215&rft.issn=0025-5564&rft.eissn=1879-3134&rft.coden=MABIAR&rft_id=info:doi/10.1016/S0025-5564(99)00055-3&rft_dat=%3Cproquest_cross%3E17508028%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17508028&rft_id=info:pmid/10701304&rft_els_id=S0025556499000553&rfr_iscdi=true |